IP Library Granted Patent US 8,946,163
Granted Patent B2
US 8,946,163 · App. 13/815,834 · Granted Feb 3, 2015

Cross-linked collagen comprising metallic anticancer agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,946,163
App. No.
13/815,834
Granted
Feb 3, 2015
Kind
B2
Abstract

The disclosure describes collagen constructs comprising anticancer agents, preferably, platinum, and related methods.

Claims (13)

1. An anticancer cross-linked collagen construct comprising:

a cross-linked collagen comprising collagen and one or more entities which cross link collagen in said construct and

an anticancer amount of platinum incorporated into the construct, wherein at least a portion of the platinum incorporated into the construct is incorporated by chelation to said entities.

2. The construct of claim 1 , wherein at least one of the cross-linking entities comprises a 1,2-benzoquinone and/or a 1,2-dihydroxy phenyl moiety.

3. The construct of claim 1 , where the platinum is chelated at least in part to the benzoquinone and/or the 1,2-dihydroxyphenyl moiety.

4. The construct of claim 1 , wherein at least one of the cross-linking entities is selected from the group consisting of entities arising from cross-linking the collagen with nordihydroguaiaretic acid (NDGA), 3,4-dyhydroxyphenylalanine, dopamine, 3,4-dihydroxybenzaldehyde, 3,4-dihydroxybenzoic acid, and tannic acid.

5. The construct of claim 1 , wherein at least one of the cross-linking entities is arising from cross-linking the collagen with NDGA.

6. The construct of claim 1 , wherein the platinum comprises platinum (II) and/or platinum (IV).

7. The construct of claim 6 wherein the platinum comprises cis-(NH 3 ) 2 Pt(II),

8. The construct of claim 1 , wherein the platinum incorporated into the construct is present in an amount of between about 0.1% to about 30%.

9. The construct of claim 1 , wherein some or all of the anticancer amount of platinum is released in vivo in contact with an aqueous medium.

10. The construct of claim 1 , wherein the anticancer cross-linked collagen construct provides a sustained release of platinum, wherein the sustained release comprises a plurality of release rates including an immediate release, an intermediate release, an extended release or any combination of release rates thereof.

11. The construct of claim 10 , wherein an effective amount of platinum is released from about 1 minute to about 60 days, or any range therein.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Feb 5, 2024
From: HAYFIN SERVICES LLP
To: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
Reel/Frame 066493/0322 →
SECURITY INTEREST Recorded Jan 25, 2024
From: MIMEDX GROUP, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 066250/0132 →
PATENT SECURITY AGREEMENT Recorded Jul 2, 2020
From: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
To: HAYFIN SERVICES LLP, AS COLLATERAL AGENT
Reel/Frame 053121/0833 →
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2020
From: BLUE TORCH FINANCE LLC, AS COLLATERAL AGENT
To: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
Reel/Frame 054075/0687 →
SECURITY INTEREST Recorded Jun 11, 2019
From: MIMEDX GROUP, INC.
To: BLUE TORCH FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 049426/0863 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2019
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: MIMEDX GROUP, INC.
Reel/Frame 048121/0835 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Oct 15, 2015
From: MIMEDX GROUP, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 036872/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2013
From: KOOB, THOMAS J.
To: MIMEDX GROUP, INC.
Reel/Frame 031057/0560 →